SUMMARY Eighteen patients with moderate to severe pulmonary hypertension were studied, nine with intracardiac shunts and nine without. 
Vasodilator treatment can produce a favourable haemodynamic response and improve exercise performance in some patients with pulmonary hypertension. In more advanced disease a vasodilator may be ineffective because pulmonary vascular obstruction has become fixed and there is no vascular reserve. In such patients these drugs may do harm. It is not known whether the response to short term treatment, if favourable, is predictive oflong term benefit. In the few studies designed to answer this question patient numbers have been too small, there has been subselection of patients after the short term vasodilator trial, or failure to standardise the long term treatment. ` Accepted for publication 9 November 1987 patients. Comparative studies suggest that some agents are better than others,' but none of these used a series of doses to cover the therapeutic range. There is therefore a need for a trial of the effects of vasodilator agents over a wide dose range to compare the short term and subsequent long term responses. Table 1 shows the clinical details ofthe 18 patients we studied. All had normal resting left ventricular function (table 2) and were stable at the time of the short term study, although three had clinical evidence of right heart failure (patients 7, 8, and 9) . The diagnosis of primary pulmonary hypertension required the exclusion ofembolic and restrictive lung disease that could have contributed to the hypertension.78 SHORT TERM STUDY measurements. Pressures were measured by Statham We tested fourteen patients (table 1) . For two weeks P23 Gb transducers connected to an E for M VR12 before the study they were kept offdrugs that affected recorder and averaged over one or more respiratory platelet function or blood coagulation. They were cycles.9 Dextrose solution (500) containing three fasted overnight and were given 10 mg diazepam as units ofheparin per ml was used to flush the lines. No premedication. The variables given in the tables and more than one litre of fluid was given during the figures were measured by standard cardiac catheter-procedure. Caffeine containing drinks were not perisation procedures. There was an interval of at least mitted.'°Total blood loss for sampling did not exceed one hour between angiography and the first set of 200 ml. (fig 2d and e) ; the rise in oxygen consumption was also greater in these patients (fig 2h) . Higher initial cardiac indices were associated with higher systemic pressure and oxygen consumption. The same was true at the end of the epoprostenol infusion (fig 2g  and h) . Right ventricular stroke work did not alter with epoprostenol (fig 2f) .
Patients and methods

METHODS
Another method of displaying the individual changes in pulmonary vascular resistance is to plot pulmonary blood flow against pulmonary artery pressure under control conditions and at the highest dose of epoprostenol (fig 3) . In all except one patient the slopes of the lines between the baseline and posttreatment values were less than the line of constant pulmonary vascular resistance. Thus all but one of the patients showed a reduction in pulmonary vascular resistance but, unfortunately, most showed no change in the ratio of pulmonary to systemic artery pressure throughout the range of epoprostenol doses examined (fig 4) . In patient 1 the ratio fell (a favourable response) and in two (patients 5 and 6) there was a considerable rise in the ratio.
Five patients had a prolonged epoprostenol infusion. The dose ranged from 2 to 8 ng/kg per minute and the duration ranged from 40 minutes to three and a half hours. All developed symptoms, and in three this led to the drug being stopped. When the effect of the dose administered during the prolonged infusion was compared with the effect of the same dose during the initial part of the study, we found no significant differences in systemic blood flow (6-0 (3 4) and 5-1 (1 4) 1/min), mean pulmonary artery pressure (66-8 (38-6) and 65-6 (39 7) mm Hg), or mean systemic pressure (78-8 (7-2) and 82 6 (15 3) mm Hg).
Nifedipine
The design of the study with nifedipine resembled that of the epoprostenol study. Doses were given sublingually at 20 minute intervals. Because nifedipine has a much longer half life than epopros- 
Effect of nifedipine on exercise performance
Only nifedipine was given in the long term study.
The design was open and the exercise performance of 11 patients after three months of treatment was compared with that one week after nifedipine was stopped (table 1). The average maintenance dose was 34 mg daily (range 10 mg twice a day to 20 mg three times a day). The maximum tolerated dose was determined by side effects, particularly headaches and dizziness. None of the patients developed right heart failure. The size of the maintenance dose was not related to the degree of response. Long term treatment with nifedipine had no effect on arterial oxygen saturation. In patients without a shunt, nifedipine increased the heart rate at rest (p < 0-01) but reduced the heart rate at peak exercise (p < 0-01). There were no such effects in the shunt group. We saw no drug induced changes in systemic blood pressure.
On the basis ofthe best of the two exercise tests, the mean work performed for all the patients while on nifedipine was 264 (range 24 to 540) W and one week after stopping nifedipine it was 243 (range 32 to 420). Overall, these differences were not statistically significant but three patients (cases 1, 2, and 3) with relatively mild disease showed considerable deterioration in symptoms and decrease in work capacity of 54, 48, and 21 00 respectively after stopping nifedipine. The remaining eight showed no improvement in symptoms or work capacity (range +7 to -24°h). Patient 4 had shown a similar favourable acute haemodynamic response to the first three patients (fig 3) , and at first had a markedly improved exercise tolerance on oral nifedipine. Her deterioration three months later probably reflected progress of her disease. She is the subject of a previous report.'4 Patients 1 to 4 had a lower pulmonary artery pressure than the others in our series (table  2) .
Patients 1 to 4 who responded to epoprostenol in the short term study-that is, they had a greater than 40%h fall in total pulmonary vascular resistance with a dose of 8 ng/kg per minute-also responded to nifedipine in the long term study; however, patient 4 deteriorated towards the end of the three month period. Patients 7 and 8 who also responded to epoprostenol infusion were in right heart failure at the time of the short term study. Neither improved on oral nifedipine and neither was fit enough to exercise. The control haemodynamic values that were the best discriminators of patients who were likely to respond were a mean pulmonary artery pressure < 50 mm Hg, a ratio of mean pulmonary to systemic pressure of <0 6 , and a ratio of total pulmonary to systemic vascular resistance of <0 7 (figs 2 to 4).
Discussion
The main object of the study was to investigate the effect of two vasodilators on the pulmonary circulation in patients with severe obliterative pulmonary vascular disease and to identify those patients who were likely to respond favourably to vasodilator treatment. Both drugs reduced the pulmonary and systemic pressure; but the maximum effect of epoprostenol was greater than that of nifedipine.
This may have been because the brief duration of action of epoprostenol permitted the infusion to be increased to the maximum tolerated dose, whereas the sublingual doses of nifedipine had a longer half life and the full effect was missed.
The fall in systemic arterial pressure was greater than the fall in pulmonary artery pressure, but when the ratio of pulmonary to systemic pressure was examined over the whole range of doses used there was no systematic change. When The long term study was open both for ethical reasons and because nifedipine induced symptoms such as headache and flushing in all the patients. The dose of nifedipine was titrated before the patient left hospital. Only four patients showed a favourable response to long term nifedipine and in the fourth patient the improvement was not maintained, probably due to progression of her disease. These four patients had responded favourably to epoprostenol in the short term study. Because the two patients with right heart failure who responded to epoprostenol did not improve with the long term administration of nifedipine, it seems that the long term response could be predicted more accurately from resting haemodynamic variables than from the effect of epoprostenol.
We suggest that short term vasodilator studies should be avoided where possible because they provide little additional information. A favourable response to the long term administration of nifedipine can be expected in patients with primary pulmonary hypertension whose disease is mild or moderate but not in those in whom it is advanced. Only three patients with chronic thromboembolic pulmonary hypertension were tested; none of them responded well in the long term. It is probable that the obstruction to pulmonary blood flow in such cases is much more mechanical rather than vasospastic. None of the patients with the Eisenmenger syndrome responded favourably; they had higher calculated pulmonary vascular resistance than the patients with pulmonary hypertension and no shunts.
We do not know whether long term benefit from nifedipine will remove the need for, or indefinitely postpone, heart-lung or lung transplantation in patients with primary pulmonary hypertension who are diagnosed and treated early3 but this seems unlikely. 26 The disease usually becomes worse. 27 It seems probable that unless the pulmonary artery pressure can be made to fall the disease process will continue to advance28 and that amelioration of the patient's symptoms by the rise in output will prove to be temporary. 29 With our present knowledge, we believe that patients with severe disability, unfavourable haemodynamic features, and particularly those with right ventricular failure, should not be denied transplantation in the hope that they will benefit from vasodilator treatment. There may, however, be a role for vasodilator treatment in patients awaiting heart-lung transplantation. 29 
Conclusions
The short term actions of epoprostenol and nifedipine in patients with severe pulmonary hypertension were very similar. Criteria for the prediction of a favourable clinical response to oral nifedipine were evaluated and resting haemodynamic variables were found to be as useful as the responses to short term treatment in the patients studied. Failure to titrate the dose has in part been responsible for a false impression that one vasodilator agent is effective when another is not3'. Epoprostenol seems to have no advantage over nifedipine that would justify attempts to use this drug for long term treatment with all the attendant difficulties, hazards, and costs ofprolonged intravenous treatment.
